E-Therapeutics hires Amgen director as new chief executive
Dr. Barlow is currently Executive Director of Corporate Development at Amgen Inc. based in Switzerland.
Dr. Barlow brings to e-Therapeutics broad experience of drug discovery, develop-ment and commercialization, acquired through regional and global roles in the biotech and pharmaceutical sector.
His previous responsibilities have included scientific, business and corporate roles with Astra Zeneca, Crucell and Johnson and Johnson.
Having completed a BSc in Chemistry from Leeds University in 1990, Dr. Barlow moved to the University of Manchester from where he gained a PhD in Chemistry in 1994.
He then spent a year at McGill University, Montreal as a post-doctoral fellow before entering the pharmaceutical industry as a senior scientist with Zeneca in Pharmaceutical R&D's Technology Access and Strategic Alliances team, of which he later became Team Leader in 1998.
Following the merger with Astra, he became a Global Manager in the Discovery and Development function, in-licensing technologies and working on the development of a range of molecules, including those in oncology, cardiovascular, respiratory and inflammatory disease areas.
Upon completion of a year as a Senior Business Analyst he was appointed Director of Corporate Development, reporting into AstraZeneca's (AZ) London HQ.
During this period he graduated from Manchester Business School with an MBA and in 2004 he stepped out of the Business Development function into a Regional commercial leadership role in Brussels covering 14 countries in CEE and Russia.
After 10 years with AZ, Dr. Barlow moved into the biotech sector working in senior business development roles for Microscience Limited and Emergent Solutions Inc..
He then spent five years running his own business (BD Solutions Limited) focused upon aiding clients on corporate development and commercialisation projects.
During this period he was CEO of Asterion, and delivered deals with Genzyme and Ipsen.
In 2010, he joined Crucell and was instrumental in the sale to Johnson & Johnson for whom he worked on a wide range of infectious disease and vaccine deals, before joining Amgen in 2012.
At Amgen he has also completed numerous deals including immuno-oncology deals with Boehringer Ingelheim and Genenta, international commercial deals with GSK and Mitsubishi Tanabe as well as playing a key part in the acquisition of Onyx and Dezima Pharma BV.
Dr. Barlow will take up the role on or before 1 May 2017, at which point he will be appointed to the e-Therapeutics Board of Directors. ■
What to read next